Literature DB >> 12468196

ACOG Committee Opinion: number 279, December 2002. Prevention of early-onset group B streptococcal disease in newborns.

.   

Abstract

During the past two decades, group B streptococci (GBS), or Streptococcus agalactiae, has emerged as an important cause of perinatal morbidity and mortality. Intrapartum administration of antibiotics to the woman (during labor or after rupture of membranes, but before delivery) has been demonstrated to reduce early-onset neonatal GBS disease. In 1996, the federal Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists, and the American Academy of Pediatrics recommended that obstetric providers adopt either a culture-based or a risk-based approach for the prevention of early-onset GBS. A recent multistate retrospective cohort study of live births in 1998 and 1999 of residents from eight areas of the Active Bacterial Core Surveillance/Emerging Infections Program network suggests that the culture-based approach is superior to the risk-based approach. The Committee on Obstetric Practice supports the new CDC recommendations that obstetric providers adopt a culture-based strategy for the prevention of early-onset GBS disease in the newborn. It is important to acknowledge that complete implementation of this complex strategy will not eliminate all cases of early-onset GBS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468196     DOI: 10.1016/s0029-7844(02)02629-7

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  21 in total

1.  Risk Factors for Late-Onset Group B Streptococcal Disease Before and After Implementation of Universal Screening and Intrapartum Antibiotic Prophylaxis.

Authors:  Jillian Pintye; Babette Saltzman; Elizabeth Wolf; Claudia S Crowell
Journal:  J Pediatric Infect Dis Soc       Date:  2015-10-12       Impact factor: 3.164

2.  Prenatal culture-based screening of Streptococcus agalactiae colonisation: resistance against erythromycin and clindamycin.

Authors:  V Lavergne; M Laverdière; A Duchesne; C Béliveau; J Delorme; A Di Zazzo; A C Labbé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

3.  Contemporary diagnosis and management of preterm premature rupture of membranes.

Authors:  Aaron B Caughey; Julian N Robinson; Errol R Norwitz
Journal:  Rev Obstet Gynecol       Date:  2008

4.  Real-time polymerase chain reaction for the rapid detection of group B streptococcal colonization in neonates.

Authors:  Girija Natarajan; Yvette R Johnson; Fan Zhang; Kang Mei Chen; Maria J Worsham
Journal:  Pediatrics       Date:  2006-07       Impact factor: 7.124

5.  Evaluation of a chromogenic agar for detection of group B streptococcus in pregnant women.

Authors:  Robin R Craven; Carol J Weber; Rebecca A Jennemann; W Michael Dunne
Journal:  J Clin Microbiol       Date:  2010-06-30       Impact factor: 5.948

6.  Prevention of Early-onset Neonatal Group B Streptococcal Disease.

Authors:  M J Soto Marió; I Valenzuela; A E Vásquez; S E Illanes
Journal:  Rev Obstet Gynecol       Date:  2013

7.  Epidemiology of early-onset neonatal group B streptococcal infection: implications for screening.

Authors:  Gerald Konrad; Alan Katz
Journal:  Can Fam Physician       Date:  2007-06       Impact factor: 3.275

8.  Prevention of neonatal group B streptococcal infection: approaches of physicians in Winnipeg, Man.

Authors:  Gerald Konrad; Susan Hauch; Christy Pylypjuk
Journal:  Can Fam Physician       Date:  2007-02       Impact factor: 3.275

Review 9.  Reappraisal of guidelines for management of neonates with suspected early-onset sepsis.

Authors:  William E Benitz; James L Wynn; Richard A Polin
Journal:  J Pediatr       Date:  2015-01-29       Impact factor: 4.406

10.  Cost-effectiveness of universal prophylaxis in pregnancy with prior group B streptococci colonization.

Authors:  Mark A Turrentine; Mildred M Ramirez; Joan M Mastrobattista
Journal:  Infect Dis Obstet Gynecol       Date:  2009-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.